AG-270

AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM[1].

Product Specifications

CAS Number

[2201056-66-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Methionine Adenosyltransferase (MAT)

Type

Reference compound

Related Pathways

Epigenetics; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ag-270.html

Purity

99.97

Solubility

DMSO : 4 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C(C2=CC=C(OC)C=C2)=C(NC3=NC=CC=C3)NC4=C(C5=CCCCC5)C(C6=CC=CC=C6)=NN14

Molecular Formula

C30H27N5O2

Molecular Weight

489.57

Precautions

H302, H315, H319, H335

References & Citations

[1]Zenon Konteatis, et al. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021 Apr 8.|[2]Marc L Hyer, et al. The MAT2A inhibitor AG-270 combines with both taxanes and gemcitabine to yield enhanced antitumor activity in patient-derived xenograft models.